Поліморфізм 399 кодона гена XRCC1 (RS2548) серед населення України

Я. М. Міщук, Є. В. Харківська, С. В. Серга, С. Є. Шкляр, В. Б. Катрій, О. К. Коляда, О. Е. Стаховський, Е. О. Стаховський, Ю. В. Вітрук, А. А. Кононенко, С. В. Демидов, Л. І. Остапченко, І. А. Козерецька

Анотація


Aim. To estimate the frequency of XRCC1 codon 399 polymorphic variants in bladder cancer patients and in a control group and define association of this polymorphism with a bladder cancer in Ukrainian patients. Methods. We determined the allele frequencies for 111 patients and 92 controls. Genotyping was performed by PCR-RELP method. Results. The distribution of genotypes in control group was: Arg/Arg – 48 % (n=44), Arg/Gln – 41.3 % (n=38), Gln/Gln – 10.7 % (n=10), whereas in group of patients with a bladder cancer the following distribution was observed: Arg/Arg – 56.8 % (n=63), Arg/Gln – 27.9 % (n=31), Gln/Gln – 15.3 % (n=17). Genotype distribution in control group was within Hardy-Weinberg equilibrium (χ2=59.7, p<0.0001), whereas in patient group it was not (χ2=0.172, p=0.678). No significant association was observed between the XRCC1 Arg399Gln polymorphism and bladder cancer risk. Conclusions. It is indicated that XRCC1 codon 399 polymorphism may not contribute to bladder cancer susceptibility in the Ukrainian population.

Keywords: bladder cancer, polymorphism, XRCC1 gene, the cancer risk.


Повний текст:

PDF

Посилання

  • Поки немає зовнішніх посилань.